Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Free Report) EVP William P. Forbes bought 50,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was acquired at an average price of $0.94 per share, for a total transaction of $47,000.00. Following the completion of the purchase, the executive vice president now directly owns 54,000 shares in the company, valued at $50,760. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Heron Therapeutics Stock Up 16.5 %
Shares of Heron Therapeutics stock traded up $0.18 during trading on Monday, hitting $1.27. 6,890,684 shares of the stock traded hands, compared to its average volume of 2,287,775. The firm’s fifty day moving average is $0.86 and its 200-day moving average is $1.25. Heron Therapeutics, Inc. has a 52 week low of $0.50 and a 52 week high of $3.41. The stock has a market cap of $190.59 million, a price-to-earnings ratio of -1.26 and a beta of 1.12.
Hedge Funds Weigh In On Heron Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the stock. American International Group Inc. grew its position in Heron Therapeutics by 5.0% during the 2nd quarter. American International Group Inc. now owns 48,168 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 2,299 shares during the last quarter. Commonwealth Equity Services LLC grew its position in Heron Therapeutics by 27.9% during the 3rd quarter. Commonwealth Equity Services LLC now owns 21,137 shares of the biotechnology company’s stock worth $89,000 after acquiring an additional 4,615 shares during the last quarter. FMR LLC grew its position in Heron Therapeutics by 4.0% during the 2nd quarter. FMR LLC now owns 140,168 shares of the biotechnology company’s stock worth $391,000 after acquiring an additional 5,369 shares during the last quarter. Arizona State Retirement System grew its position in Heron Therapeutics by 18.9% during the 1st quarter. Arizona State Retirement System now owns 34,448 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 5,487 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in Heron Therapeutics by 2.0% during the 1st quarter. Bank of New York Mellon Corp now owns 304,733 shares of the biotechnology company’s stock worth $1,744,000 after acquiring an additional 5,882 shares during the last quarter. 81.77% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
- Five stocks we like better than Heron Therapeutics
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Plan to own one retailer? Make it this one
- How to Invest in Music Stocks
- Target these 3 hot retail stocks for Black Friday deals
- How to Use the MarketBeat Dividend Calculator
- Dell Technologies breaks out, riding high on AI
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.